TB-500 (Thymosin Beta-4)

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide involved in actin regulation and cell migration. It has been studied for its apparent role in wound healing, angiogenesis, and tissue repair across cardiac and musculoskeletal systems. Preclinical research suggests the peptide may support migration of repair cells to damaged tissue and modulate inflammatory responses. Much of the supporting evidence originates from animal models, with human research remaining preliminary. It is commonly referenced in recovery-focused research contexts. Reported benefits include studied for systemic wound healing support, investigated for angiogenesis promotion in damaged tissue, explored in animal models for cardiac tissue repair.

Reported ranges run 2-5 mg. A low protocol is 2 mg once weekly, and a high protocol is 5 mg twice weekly. This is reference information, not a dosing recommendation.

Short plasma half-life estimated in minutes to a few hours, though tissue-level effects are reported to persist longer. That is what sets the dosing frequency, and it is why the timing guidance is morning.

Subcutaneous: into fat, under the skin. Typically injected systemically rather than at the injury site, since its effects are not considered strictly localized.

4-6 weeks loading, then maintenance on, followed by 4-6 weeks off. Often cycled with an initial loading phase followed by lower-frequency maintenance dosing.

Reported side effects include injection site reaction, headache, fatigue, lightheadedness, limited human safety data. Evidence level for this compound is moderate evidence.